A preclinical pharmacokinetic modeling approach to the biopharmaceutical characterization of immediate and microsphere-based sustained release pulmonary formulations of rifampicin

European Journal of Pharmaceutical Sciences

Volumn 48, Issue 1-2, 2013, Pages 223-230

  Doan, T V P ^a,b   Gregoire N ^a,b   Lamarche, I ^a,b   Gobin, P ^a,c   Marchand, S ^a,b,c   Couet, W ^a,b,c   Olivier, J C ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ DE POITIERS   (France)

^c POITIERS UNIVERSITY HOSPITAL   (France)

Author keywords

Cyclodextrin; Lung delivery; Pharmacokinetic modeling; PLGA microsphere; Rat; Rifampicin

Indexed keywords

MICROSPHERE; RIFAMPICIN;

AEROSOL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DETERMINATION; LUNG ALVEOLUS EPITHELIUM; LUNG LAVAGE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SUSTAINED RELEASE FORMULATION;

ADMINISTRATION, INHALATION; ANIMALS; ANTIBIOTICS, ANTITUBERCULAR; BETA-CYCLODEXTRINS; BRONCHOALVEOLAR LAVAGE FLUID; DELAYED-ACTION PREPARATIONS; LUNG; MALE; MICROSPHERES; MODELS, BIOLOGICAL; RATS; RATS, WISTAR; RIFAMPIN;

EID: 84870322132     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2012.10.024     Document Type: Article

References (22)

1. S. Agrawal, and R. Panchagnula Implication of biopharmaceutics and pharmacokinetics of rifampicin in variable bioavailability from solid oral dosage forms Biopharm. Drug Dispos. 26 2005 321 334
2. S.L. Beal Ways to fit a PK model with some data below the quantification limit J. Pharmacokinet. Pharmacodyn. 28 2001 481 504
3. C. Becker, J.B. Dressman, H.E. Junginger, S. Kopp, K.K. Midha, V.P. Shah, S. Stavchansky, and D.M. Barends Biowaiver monographs for immediate release solid oral dosage forms: rifampicin J. Pharm. Sci. 98 2009 2252 2267
4. J.B. Bulitta, A. Bingolbali, B.S. Shin, and C.B. Landersdorfer Development of a new pre- and post-processing tool (SADAPT-TRAN) for nonlinear mixed-effects modeling in S-ADAPT AAPS J. 13 2011 201 211
5. I. Coowanitwong, V. Arya, P. Kulvanich, and G. Hochhaus Slow release formulations of inhaled rifampin AAPS J. 10 2008 342 348
6. P. Costa, and J.M. Sousa Lobo Modeling and comparison of dissolution profiles Eur. J. Pharm. Sci. 13 2001 123 133
7. S. Díez, and C. Tros de Ilarduya Versatility of biodegradable poly(D,L-lactic-co-glycolic acid) microspheres for plasmid DNA delivery Eur. J. Pharm. Biopharm. 63 2006 188 197
8. T.V.P. Doan, W. Couet, and J.C. Olivier Formulation and in vitro characterization of inhalable rifampicin-loaded PLGA microspheres for sustained lung delivery Int. J. Pharm. 414 2011 112 117
9. D.A. Edwards, J. Hanes, G. Caponetti, J. Hrkach, A. Ben-Jebria, M.L. Eskew, J. Mintzes, D. Deaver, N. Lotan, and R. Langer Large porous particles for pulmonary drug delivery Science 276 1997 1868 1871
10. F. Gagnadoux, A.L. Pape, E. Lemarie, S. Lerondel, I. Valo, V. Leblond, J.-L. Racineux, and T. Urban Aerosol delivery of chemotherapy in an orthotopic model of lung cancer Eur. Respir. J. 26 2005 657 661
11. K. Hirota, T. Hasegawa, T. Nakajima, H. Inagawa, C. Kohchi, G. Soma, K. Makino, and H. Terada Delivery of rifampicin-PLGA microspheres into alveolar macrophages is promising for treatment of tuberculosis J. Control. Release 142 2010 339 346
12. R. Karki, G. Subramanya, and N. Udupa Formulation and evaluation of coencapsulated rifampicin and isoniazid liposomes using different lipids Acta Pharm. Sci. 51 2009 177 188
13. S. Kiem, and J.J. Schentag Interpretation of antibiotic concentration ratios measured in epithelial lining fluid Antimicrob. Agents Chemoth. 52 2008 24 36
14. S. Marchand, P. Gobin, J. Brillault, S. Baptista, C. Adier, J.C. Olivier, O. Mimoz, and W. Couet Aerosol therapy with colistin methanesulfonate: a biopharmaceutical issue illustrated in rats Antimicrob. Agents Chemoth. 54 2010 3702 3707
15. J.W. Mouton, U. Theuretzbacher, W.A. Craig, P.M. Tulkens, H. Derendorf, and O. Cars Tissue concentrations: do we ever learn? J. Antimicrob. Chemoth. 61 2008 235 237
16. P. Muttil, C. Wang, and A.J. Hickey Inhaled drug delivery for tuberculosis therapy Pharm. Res. 26 2009 2401 2416
17. T. Onoshita, Y. Shimizu, N. Yamaya, M. Miyazaki, M. Yokoyama, N. Fujiwara, T. Nakajima, K. Makino, H. Terada, and M. Haga The behavior of PLGA microspheres containing rifampicin in alveolar macrophages Colloids Surf. B: Biointerfaces 76 2010 151 157
18. S. Suarez, P. O'Hara, M. Kazantseva, C.E. Newcomer, R. Hopfer, D.N. McMurray, and A.J. Hickey Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: screening in an infectious disease model Pharm. Res. 18 2001 1315 1319
19. J.C. Sung, D.J. Padilla, L. Garcia-Contreras, J.L. Verberkmoes, D. Durbin, C.A. Peloquin, K.J. Elbert, A.J. Hickey, and D.A. Edwards Formulation and pharmacokinetics of self-assembled rifampicin nanoparticle systems for pulmonary delivery Pharm. Res. 26 2009 1847 1855
20. F. Tewes, J. Brillault, W. Couet, and J.C. Olivier Formulation of rifampicin-cyclodextrin complexes for lung nebulization J. Control. Release 129 2008 93 99
21. D. Traini, and P.M. Young Delivery of antibiotics to the respiratory tract: an update Expert Opin. Drug Deliv. 6 2009 897 905
22. Y. Yang, N. Bajaj, P. Xu, K. Ohn, M.D. Tsifansky, and Y. Yeo Development of highly porous large PLGA microparticles for pulmonary drug delivery Biomaterials 30 2009 1947 1953